Kairos Pharma Ltd. Common Stock (KAPA)

FairStock Score: 22/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Kairos as a Graham-style analyst, not a speculator. This is a clinical-stage biopharmaceutical company with no revenue in any filed period I can see. Its losses are widening: net loss was $1.8 million in FY2023, $2.6 million in FY2024, and $5.4 million in FY2025. In fiscal Q1 2026, the quarter ended 2026-03-31, net loss was $1.7 million; in fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $1.4 million. Trailing free cash flow is about -$4.0 million, a -20.2% FCF yield on the $19.6 million market cap. The FairStock P/E is -0.42 and P/B is 0.61 at the 2026-10-13 close, but the P/B discount only matters if the book value is durable; with cash burn, it may not be. Business quality is unproven. One employee and no sales mean no economic moat I can identify; the value rests on ENV 105, an antibody in Phase 2 for prostate cancer and Phase 1 testing. FairStock's Piotroski F-Score of 1/9 is poor, while its Altman Z-Score of 39.83 suggests the balance sheet is not near bankruptcy on that calculation. ROE is -113.96% and ROCE is -66.91%, confirming capital is being consumed. The Peter Lynch category is none because of losses in each of the last three years. Growth is negative in earnings terms: losses are not shrinking. At $0.83, this is an option on clinical success, not a Buffett-style bargain.

In plain English: Kairos Pharma is a tiny clinical-stage company working on cancer treatments, with no product sales yet and no profits. It loses money, spends cash, and its losses have been getting bigger in recent years. Its stock price is low compared with the value of its assets on paper, but because there are no earnings or revenue, the price mostly reflects hopes for future drug trials rather than today's business.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer